&lt;p&gt;A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy&lt;/p&gt;

Majdinasab, Nastaran; Kaveyani, Hossein; Azizi, M.

doi:10.2147/dddt.s185995

Cited by 32 publications

(27 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, one of the studies raised some concerns, 22 and the other two were classified as low risk. 23,24 Evidence quality assessment was based on GRADE. 18 The details are shown in Table 3.…”

Section: Studyqualityassessmentmentioning

confidence: 99%

Comparison of efficacy and safety of gabapentin and duloxetine in painful diabetic peripheral neuropathy: A systematic review and meta‐analysis of randomised controlled trials

Lee

et al. 2021

Int J Clin Pract

View full text Add to dashboard Cite

Background:In patients with diabetes mellitus, painful diabetic peripheral neuropathy (PDPN) is a frequent complication and can cause poor quality of life. We compared the efficacy and safety of duloxetine with those of gabapentin in patients with PDPN through a systematic review and meta-analysis of randomised controlled trials. MaterialsandMethods:PubMed, Embase and the Cochrane Library were searched for eligible studies published from database inception to January 2021. Visual Analogue Scale (VAS), sleep interference score, Clinical Global Impression of Change (CGIC), Patient Global Impression of Change (PGIC), Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathic Examination (DNE) score, Neuropathic Disability Score (NDS) and side effects were used to compare duloxetine and gabapentin in patients with PDPN. Results:Three eligible randomised controlled trials involving 290 patients were included. No significant differences were observed between patients receiving duloxetine and gabapentin with respect to VAS (mean change difference = −1.23, 95% CI, −6.09 to 3.62; P = .62), sleep interference score (mean change difference = 0.42, 95% CI, −0.15 to 1.00; P = .15), CGIC (mean difference = 0.04, 95% CI, −0.11 to 0.20; P = .60), PGIC (mean difference= 0.24, 95% CI, −0.13 to 0.60; P = .21), DNS (mean change difference = 0.14, 95% CI, −0.35 to 0.63; P = .58), DNE (mean change difference = 0.26, 95% CI, −0.35 to 0.86; P = .41) and NDS (mean change difference = 0.30, 95% CI, −0.02 to 0.63; P = .07).Conclusions:No significant differences were observed in the efficacy of duloxetine and gabapentin when treating patients with PDPN.

show abstract

Section: Studyqualityassessmentmentioning

confidence: 99%

Comparison of efficacy and safety of gabapentin and duloxetine in painful diabetic peripheral neuropathy: A systematic review and meta‐analysis of randomised controlled trials

Lee

et al. 2021

Int J Clin Pract

View full text Add to dashboard Cite

show abstract

“…The gabapentin group reported more adverse events, which may be because of higher than normal recommend dose (900 mg/day) used in the study. 20 Devi et al 11 evaluated clinical efficacy of gabapentin, duloxetine, and pregabalin in PDN. In this trial, the gabapentin, duloxetine, and pregabalin groups showed a significant reduction in VAS at the end of 12 weeks (P < .05) but there was no significant difference between the groups.…”

Section: Discussionmentioning

confidence: 99%

A randomized control trial of duloxetine and gabapentin in painful diabetic neuropathy

Khasbage

Shukla

Sharma

et al. 2021

Journal of Diabetes

View full text Add to dashboard Cite

Background: To analyze the efficacy and safety of duloxetine and gabapentin in painful diabetic neuropathy (PDN). Methods: A randomized, open-label, active control, 12-week trial was conducted. A total of 86 participants were randomized in 1:1 ratio into gabapentin 300 mg and duloxetine 60 mg groups. The primary efficacy objective was comparison of mean change in Visual Analogue Scale (VAS) (0-100 points) scores between duloxetine and gabapentin. The symptom scores and adverse events were assessed as secondary outcomes.Results: Statistically significant (P value<.001) improvement was observed in VAS scores in both duloxetine group and gabapentin group at 12 weeks as compared to baseline. However, no significant difference in VAS scores between duloxetine and gabapentin. Similar improvement in diabetic neuropathy symptoms (DNS), diabetic neuropathy examination (DNE), and neuropathic disability score (NDS) was observed in either group over 12 weeks. There were no significant differences in DNS (P = 0.578), DNE (P = 0.410), and NDS (P = 0.071) scores between the two treatment groups. The overall safety evaluation of both duloxetine and gabapentin were similar. The most common adverse events reported were gastrointestinal. Conclusion:The results indicated that both drugs were effective for the symptomatic relief from PDN and had similar efficacy. Follow-up of patients was only for 12 weeks and therefore the long-term efficacy and safety of the study drugs could not be assessed. Highlights• There is significant decrease in pain score and symptom score like diabetic neuropathy symptoms, diabetic neuropathy examination, and neuropathic disability score with duloxetine and gabapentin.• Equivalence of duloxetine with gabapentin was established with regard to Visual Analogue Scale (VAS) scores. † Had equal contribution in this randomized control trial.

show abstract

“…In yet another study venlafaxine was found to be inferior to pregabalin in this regard [30]. Duloxetine monotherapy was found to be an equally potent agent as gabapentin for the treatment of Diabetic Polyneuropathy pain, however with much better tolerability [31]. Likewise, duloxetine showed efficacy comparable to pregabalin for the treatment of such pain [32].…”

Section: Discussionmentioning

confidence: 99%

"Role of Different Pain Killers in Control of Diabetic Neuropathy Pain-A Review"

Blair¹,

Khalil²,

Arshad³

et al. 2021

BJSTR

View full text Add to dashboard Cite

Diabetic neuropathy [DN) is a continual complication of diabetes mellitus (DM). It has an approximate pervasiveness ranging from thirty to fifty percent in subjects suffering from this disease, depending on the technique utilized for diagnosis. Additionally, DM has remained the top causative factor of polyneuropathy in the modern world. As much as fifty percent of the polyneuropathies are related to DM. It is more common in chronic DM: it negatively impacts the quality of life (QOL) in those suffering from it. Polyneuropathies cause chronic neuropathic pain, resulting in depression, anxiety, and insomnia among sufferers. Diabetic neuropathy is a painful and disabling condition that has enormous incurring costs in terms of disrupted quality of life and financial implication while treating its complications. Various pain killers have been tried in this regard with varying results. Aim of this review was to delve into various drugs outcomes in this regard.

show abstract

<p>A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy</p>

Cited by 32 publications

References 26 publications

Comparison of efficacy and safety of gabapentin and duloxetine in painful diabetic peripheral neuropathy: A systematic review and meta‐analysis of randomised controlled trials

Comparison of efficacy and safety of gabapentin and duloxetine in painful diabetic peripheral neuropathy: A systematic review and meta‐analysis of randomised controlled trials

A randomized control trial of duloxetine and gabapentin in painful diabetic neuropathy

"Role of Different Pain Killers in Control of Diabetic Neuropathy Pain-A Review"

Contact Info

Product

Resources

About